Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study (LBA 10)
Saved in:
Published in | Gynecologic oncology Vol. 176; pp. S42 - S43 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
01.09.2023
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!